The biotech stock's price-to-earnings-to-growth (PEG) ratio is a super-low 0.58, according to the London Stock Exchange Group (LSEG). Any PEG ratio below 1.0 is viewed as an attractive valuation.

The stock of Vertex Pharmaceuticals Incorporated VRTX has declined around 1.2% in the past three months, losing almost $3 ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” second ...

Jupiter Endovascular today announced the first two patients treated in a study of its Vertex pulmonary embolectomy system.

Discover why Vertex stock is undervalued with the potential of VX-548 as a groundbreaking pain treatment drug in the ...

The FDA should have more big news for Vertex only a few weeks later. It expects to announce an approval decision on ...

Nick Li is global HEOR lead for hemoglobinopathies at Vertex Pharmaceuticals. Below he explains why this type of research is ...

Kendric Cromer, 12, is among the first patients to be treated with gene therapy just approved by the F.D.A. that many other ...

Jupiter Endovascular, Inc. announced that the first two patients were treated in the SPIRARE I trial of the Vertex pulmonary ...

No patients have received Casgevy, CRISPR Therapeutics and Vertex Pharmeceuticals’ recently approved sickle cell gene therapy ...

One is that, also in our pain franchise ... And we intend to fully develop both of these markets at Vertex. We see them both as specialty markets. And longer-term, given the mechanism of action, we ...